A Phase 3 interventional study of MenACWY-CRM in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 4 sites in Russian Federation. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Meningococcal Infections by Novartis — none open to participants now, none under way, none of them phase 3. Meningococcal Infections · Novartis.
Among the 60 studies in Meningococcal Infections by Novartis, this one is the 45th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2012, is one of 27 in phase 3, and was the 53rd registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →None of the 60 studies in Meningococcal Infections by Novartis is open now. The open studies under Meningococcal Infections, anywhere →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 2 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 24 · Phase 3 30 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is below the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 484 across the 57 interventional studies, 393 across the 3 observational. Of the 59 that completed or were terminated, 48 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Meningococcal Infections by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the immune response and safety following a single dose of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy children, adolescents and adults in Russia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals eligible for enrollment in this study were those:
Who were of any gender, from the age of 2 years and above at the time of visit 1, and to whom the nature of the study had been described and:
Who were in good health as determined by
Exclusion Criteria:
Individuals not eligible to be enrolled in the study were those:
Who had received any vaccines within 14 days (for inactivated vaccines) or 28 days (for ) prior to enrollment in this study or who were planning to receive any vaccine within 30 days from the study vaccines.
(Exception: Influenza vaccine might be administered up to 15 days prior to study vaccination and at least 15 days after study vaccination).
Who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MenACWY-CRM
Biological: MenACWY-CRM
1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
Percentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination
Immunogenicity was measured as the percentages of overall subjects with hSBA (human serum bactericidal assay) seroresponse, directed against Neisseria meningitidis (N meningitidis) serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM (day 29). The seroresponse is defined as the percentages of subjects achieving hSBA ≥1:8 postvaccination with a prevaccination hSBA \<1:4 and the percentages of subjects achieving at least four-fold increases in postvaccination hSBA from day 1 in subjects with a baseline hSBA ≥1:4
Time frame: Day 29
Percentages of Subjects With Seroresponse After MenACWY-CRM Vaccination, by Age Group
Immunogenicity was measured as the percentages of subjects stratified by age group with hSBA response, directed against N meningitidis serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM
Time frame: Day 29
Geometric Mean Titers (GMTs) of Subjects at Baseline and After MenACWY-CRM Vaccination
Immunogenicity was measured as hSBA GMTs, against N meningitidis serogroups A, C, W and Y, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group
Time frame: Days 1 and 29
Percentages of Subjects With hSBA Titer ≥1:8 at Baseline and After MenACWY-CRM Vaccination
Immunogenicity was measured as the percentages of subjects with hSBA titer ≥1:8, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group
Time frame: Days 1 and 29
Percentages of Subjects Aged 2 Through 5 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination
Safety was assessed as the percentages of subjects aged 2 through 5 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination
Time frame: Within days 1 through 7 postvaccination
Percentages of Subjects Aged ≥6 Years With Solicited Local and Systemic AEs After MenACWY-CRM Vaccination
Safety was assessed as the percentages of subjects aged ≥6 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination, overall and by age group
Time frame: Within days 1 through 7 postvaccination
Percentages of Subjects Reporting Unsolicited Adverse Events (AEs) After MenACWY-CRM Vaccination
Safety was assessed in terms of percentages of subjects who reported all the adverse events (AEs) occurring from day 1 through 7, medically attended AEs, SAEs and AEs resulting in premature withdrawal, from day 1 through 29, after MenACWY-CRM vaccination, overall and by age group
Time frame: AEs occurring from day 1 through 7, medically attended AEs, SAEs and AEs resulting in premature withdrawal, from day 1 through 29
Subjects were enrolled at 5 centers in Russia
| Milestone | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years |
|---|---|---|---|
| Started | 66 | 66 | 66 |
| Completed | 65 | 66 | 66 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Immunogenicity was measured as the percentages of overall subjects with hSBA (human serum bactericidal assay) seroresponse, directed against Neisseria meningitidis (N meningitidis) serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM (day 29). The seroresponse is defined as the percentages of subjects achieving hSBA ≥1:8 postvaccination with a prevaccination hSBA \<1:4 and the percentages of subjects achieving at least four-fold increases in postvaccination hSBA from day 1 in subjects with a baseline hSBA ≥1:4
| Percentage of subjects | Overall (≥2 Years) |
|---|---|
| MenA | 85 (79 to 90) |
| MenC | 74 (67 to 80) |
| MenW | 60 (53 to 67) |
| MenY | 83 (77 to 88) |
Immunogenicity was measured as the percentages of subjects stratified by age group with hSBA response, directed against N meningitidis serogroups A, C, W and Y, 28 days after one vaccination of MenACWY-CRM
| Percentage of subjects | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years |
|---|---|---|---|
| MenA | 89 (78 to 95) | 89 (79 to 96) | 77 (65 to 86) |
| MenC | 69 (56 to 80) | 82 (70 to 90) | 71 (58 to 81) |
| MenW | 73 (60 to 83) | 51 (38 to 63) | 57 (44 to 69) |
| MenY | 77 (65 to 87) | 88 (77 to 95) | 85 (74 to 92) |
Immunogenicity was measured as hSBA GMTs, against N meningitidis serogroups A, C, W and Y, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group
| human serum bactericidal assay titer | Overall (≥2 Years) | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years |
|---|---|---|---|---|
| MenA (Day 1) | 2.35 (2.17 to 2.55) | 2.17 (1.79 to 2.62) | 2.43 (2.01 to 2.93) | 2.61 (2.11 to 3.23) |
| MenA (Day 29) | 93 (73 to 119) | 67 (38 to 119) | 134 (77 to 233) | 76 (41 to 143) |
| MenC (Day 1) | 4.07 (3.45 to 4.8) | 3.16 (2.18 to 4.57) | 3.59 (2.5 to 5.15) | 6.68 (4.43 to 10) |
| MenC (Day 29) | 59 (43 to 81) | 28 (14 to 56) | 47 (24 to 92) | 112 (52 to 243) |
| MenW (Day 1) | 12 (9.42 to 15) | 7.93 (4.69 to 13) | 21 (13 to 36) | 13 (7.16 to 23) |
| MenW (Day 29) | 111 (89 to 139) | 94 (56 to 155) | 117 (72 to 191) | 143 (83 to 248) |
| MenY (Day 1) | 2.93 (2.61 to 3.28) | 3.02 (2.33 to 3.92) | 3.73 (2.89 to 4.82) | 2.74 (2.05 to 3.66) |
| MenY (Day 29) | 58 (46 to 74) | 32 (18 to 56) | 67 (39 to 115) | 80 (43 to 147) |
Immunogenicity was measured as the percentages of subjects with hSBA titer ≥1:8, at baseline (day 1) and 28 days after MenACWY-CRM vaccination (day 29), overall and by age group
| Percentage of Subjects | Overall (≥2 Years) | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years |
|---|---|---|---|---|
| MenA (Day 1) | 6 (3 to 10) | 2 (0.04 to 9) | 5 (1 to 13) | 11 (4 to 21) |
| MenA (Day 29) | 89 (83 to 93) | 89 (78 to 95) | 92 (83 to 97) | 85 (74 to 92) |
| MenC (Day 1) | 26 (20 to 33) | 13 (6 to 23) | 17 (9 to 28) | 49 (37 to 62) |
| MenC (Day 29) | 84 (78 to 89) | 76 (63 to 86) | 86 (75 to 93) | 89 (79 to 96) |
| MenW (Day 1) | 57 (50 to 64) | 30 (19 to 43) | 71 (58 to 81) | 69 (57 to 80) |
| MenW (Day 29) | 97 (93 to 99) | 95 (87 to 99) | 98 (92 to 100) | 97 (89 to 100) |
| MenY (Day 1) | 16 (11 to 22) | 10 (4 to 20) | 15 (8 to 26) | 22 (12 to 33) |
| MenY (Day 29) | 88 (82 to 92) | 79 (67 to 88) | 94 (85 to 98) | 89 (79 to 96) |
Safety was assessed as the percentages of subjects aged 2 through 5 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination
| Percentage of subjects | ≥2 to ≤5 Years | ≥2 to ≤3 Years |
|---|---|---|
| Tenderness | 41 | 39 |
| Erythema | 26 | 28 |
| Induration | 19 | 17 |
| Change in Eating Habits | 4 | 6 |
| Sleepiness | 33 | 28 |
| Irritability | 26 | 17 |
| Vomiting | 4 | 0 |
| Diarrhea | 11 | 11 |
| Rash | 4 | 6 |
| Fever (≥38 °C) | 4 | 6 |
| Use of analgesics/antipyretics | 7 | 0 |
Safety was assessed as the percentages of subjects aged ≥6 years who reported solicited local and systemic AEs within days 1 through 7 after MenACWY-CRM vaccination, overall and by age group
| Percentage of Subjects | Overall (≥6 Years) | ≥6 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years |
|---|---|---|---|---|
| Pain | 48 | 42 | 50 | 50 |
| Erythema | 18 | 18 | 18 | 17 |
| Induration | 14 | 11 | 17 | 12 |
| Chills | 9 | 8 | 8 | 12 |
| Nausea | 8 | 3 | 11 | 8 |
| Malaise | 20 | 16 | 23 | 20 |
| Myalgia | 19 | 13 | 29 | 14 |
| Arthralgia | 9 | 3 | 11 | 11 |
| Headache | 25 | 18 | 27 | 27 |
| Rash | 2 | 3 | 0 | 5 |
| Fever (≥38 °C) | 3 | 5 | 3 | 2 |
| Use of analgesic/antipyretics | 11 | 18 | 9 | 9 |
Safety was assessed in terms of percentages of subjects who reported all the adverse events (AEs) occurring from day 1 through 7, medically attended AEs, SAEs and AEs resulting in premature withdrawal, from day 1 through 29, after MenACWY-CRM vaccination, overall and by age group
| percentage of subjects | Overall (≥2 Years) | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years |
|---|---|---|---|---|
| Any AEs(days 1 through 7) | 17 | 20 | 12 | 18 |
| At least possibly related AEs (days 1 through 7) | 10 | 3 | 9 | 18 |
| SAE(days 1 through 29) | 0 | 0 | 0 | 0 |
| At least possibly related SAE(days 1 through 29) | 0 | 0 | 0 | 0 |
| Medically attended AE(days 1 through 29) | 4 | 8 | 2 | 3 |
| Premature withdrawal due to AE(days 1 through 29) | 0 | 0 | 0 | 0 |
Collected over From day 1 through day 29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ≥2 to ≤10 Years | — | 0/65 (0%) | 42/65 (64.6%) |
| ≥11 to ≤17 Years | — | 0/66 (0%) | 42/66 (63.6%) |
| ≥18 Years | — | 0/66 (0%) | 44/66 (66.7%) |
| Overall (≥2 Years) | — | 0/197 (0%) | 128/197 (65%) |
| Event | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years | Overall (≥2 Years) |
|---|---|---|---|---|
| Injection site painGeneral disorders | 27/65 | 33/66 | 33/66 | 93/197 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/65 | 19/66 | 9/66 | 33/197 |
| HeadacheNervous system disorders | 8/65 | 18/66 | 18/66 | 44/197 |
| MalaiseGeneral disorders | 6/65 | 15/66 | 13/66 | 34/197 |
| Injection site erythemaGeneral disorders | 12/65 | 13/66 | 10/66 | 35/197 |
| Injection site indurationGeneral disorders | 8/65 | 11/66 | 8/66 | 27/197 |
| SomnolenceNervous system disorders | 9/65 | 1/66 | 0/66 | 10/197 |
| ChillsGeneral disorders | 3/65 | 5/66 | 8/66 | 16/197 |
| IrritabilityGeneral disorders | 7/65 | 0/66 | 0/66 | 7/197 |
| NauseaGastrointestinal disorders | 1/65 | 7/66 | 5/66 | 13/197 |
| Age, Continuous(year) | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years | Total |
|---|---|---|---|---|
| Mean | 6.0 ± 2.7 | 13.8 ± 2.1 | 38.8 ± 12.5 | 19.6 ± 15.9 |
| Sex: Female, Male(Participants) | ≥2 to ≤10 Years | ≥11 to ≤17 Years | ≥18 Years | Total |
|---|---|---|---|---|
| FEMALE | 35 | 29 | 44 | 108 |
| MALE | 31 | 37 | 22 | 90 |
The record gives a start of Nov 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.